09:26 AM EDT, 05/20/2025 (MT Newswires) -- Tempus AI ( TEM ) said Tuesday it is collaborating with Verastem ( VSTM ) to develop a companion diagnostic test for a combination treatment for recurrent low-grade serous ovarian cancer.

Tempus said it completed confirmatory testing in Verastem's ( VSTM ) phase 2 clinical trial, which was the basis of the US Food and Drug Administration's recent accelerated approval of the combination of avutometinib and defactinib.

The company said its xT companion diagnostic assay is being leveraged as an investigational assay to prospectively evaluate KRAS status in patients with recurrent low-grade serous ovarian cancer and categorize patients into KRAS-mutation or KRAS-wild type groups for analysis in the primary and secondary endpoints of Verastem's ( VSTM ) global phase 3 clinical trial.